Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | CASP9 | P55211 | 1/20 | 0.66 |
| ▸ | CASP6 | P55212 | 1/20 | 0.66 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.66 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.66 |
| ▸ | AHR | P35869 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FER | P16591 | 1/20 | 0.55 |
| ▸ | LTK | P29376 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084317 | 0.85 | TDP2 (0.61) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL2086488 | 0.84 | NPC1 (0.62) | TDP2CASP3CASP7CASP9CASP6 | |
| Fluorene SCHEMBL28396879 | 0.82 | AHR (0.81) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL11105121 | 0.81 | CHEK1 (0.53) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL23242558 | 0.81 | CSNK1G1 (0.56) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3408012 | 0.81 | AHR (0.58) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL1816980 | 0.79 | AHR (0.63) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL29580380 | 0.79 | TDP2 (1.00) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL422023 | 0.79 | TDP2 (1.00) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL7342177 | 0.78 | AHR (0.52) | TDP2CASP3CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0149840-B1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | claimed |
| EP-0149840-A1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1985-07-31 | — | — | EP | claimed |
| EP-0089322-A1 | Tricyclic derivatives of 5,6-dihydro-11H-dibenzo(B,E)azepin-6-one having pharmacological avtivity, and method for their preparation | A. Menarini S.a.S. (IT) | 1983-09-21 | — | — | EP | claimed |
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | TEXAS A & M UNIV SYS (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | TEXAS A & M UNIV SYS (US) | 2025-03-13 | — | — | US | disclosed |
| CN-114929688-B | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4048667-B1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANOIC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4333821-A1 | INHIBITORS OF SARS-COV-2 | The Texas A&M University System (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-115215800-B | Dibenzocyclyl-cyclic amino ether derivative or salt, and preparation method and application thereof | 赣江中药创新中心 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022235813-A1 | INHIBITORS OF SARS-COV-2 | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-0089322-B1 | TRICYCLIC DERIVATIVES OF 5,6-DIHYDRO-11H-DIBENZO(B,E)AZEPIN-6-ONE HAVING PHARMACOLOGICAL AVTIVITY, AND METHOD FOR THEIR PREPARATION | A. Menarini S.a.S. (IT) | 1987-06-16 | — | — | EP | disclosed |
| EP-0089322-B1 | TRICYCLIC DERIVATIVES OF 5,6-DIHYDRO-11H-DIBENZO(B,E)AZEPIN-6-ONE HAVING PHARMACOLOGICAL AVTIVITY, AND METHOD FOR THEIR PREPARATION | A. Menarini S.a.S. (IT) | 1987-06-16 | — | — | EP | disclosed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | disclosed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | disclosed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | disclosed |
| EP-0149840-A1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0149840-A1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0149840-A1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0089322-A1 | Tricyclic derivatives of 5,6-dihydro-11H-dibenzo(B,E)azepin-6-one having pharmacological avtivity, and method for their preparation | A. Menarini S.a.S. (IT) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | ACE2, ACE, TMPRSS2 | TDP2 1887/4885CASP3 463/4885CASP7 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.